The Federal Trade Commission has begun outlining its case against Edwards Lifesciences' proposed purchase of the heart ...

A federal commission is warning that the U.S. is losing its innovative edge, arguing that the nation needs to “reimagine the ...

AbbVie is opening submissions for an award that will provide one Canadian biotech with free access to lab space and executive ...

GE HealthCare is raising the curtain on its spearhead into the field of photon-counting CT, the Photonova Spectra, with an ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

Johnson & Johnson MedTech is expanding its stroke-focused R&D in Ireland, building on previous investments and coming on the ...